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INTRODUCTION
The proposed standards are directed towards the 
management of diabetic women during pregnancy or 
puerperium, as well as, women who intend on becoming 
pregnant or whose hyperglycemia was first detected dur-
ing pregnancy. 
The recommendations are a revised version of the stand-
ards originally published in Ginekologia Polska in 2011 and 
2015, respectively. The update focuses on the nomencla-
ture of diabetes in pregnancy standards of diagnosis and 
therapeutic goals, which define the proper management of 
diabetes in pregnancy.
Classification
The Polish Diabetic Society (PTD) classifies diabetes in 
pregnancy as follows:
 Ū Pregestational Diabetes (PGDM) — when 
a woman with diabetes becomes pregnant (regard-
less of the type of diabetes)
 Ū Hyperglycemia — first diagnosed during pregnan-
cy (this group includes patients with gestational dia-
betes, as well as, other types of diabetes, diagnosed 
during pregnancy)
1. PREGESTATIONAL DIABETES MELLITUS 
Despite the significant progress in diabetology, the risk 
of obstetric, maternal and neonatal complications remain 
substantially higher in patients with PGDM as compared to 
non-diabetic patients. For this reason, pregnancy in a dia-
betic should be managed in a specialized facility (III° centre) 
with personnel experienced in managing PGDM pregnancy. 
The team should consist of:
1. Obstetrician
2. Diabetologist
3. Neonatologist 
4. Educational nurse, dietitian
1.1. Management model of pregnant patients 
with PGDM
1.1.1. Preparing for pregnancy
All diabetic women, who are planning a pregnancy, 
as well as, those in the course of pregnancy and/or post-
partum, should remain under the care of an experienced 
diabetology-obstetrics team. The goal is to optimize the 
treatment of diabetes (including diabetic and dietetic edu-
cation), increasing prevention, improving prognosis and 
treating its chronic complications (Tab. 1). 
Due to the clinically proven negative impact of hypergly-
cemia on the fetus during the first trimester, the main goal 
of diabetologists and obstetricians should be providing care 
preceding pregnancy, referred to as the period of planning 
the pregnancy; optimally 3–6 months before conception. 
All diabetic patients of childbearing age should be edu-
cated about irreversible complications and the potential 
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health impact of unplanned pregnancy on progeny, includ-
ing birth defects.
Contraception in diabetes
Choosing an optimal method of contraception is indi-
spensable to planning a pregnancy. This applies to patients 
who are planning the pregnancy, as well as, those who are 
not.
Patients should be informed that oral contraceptive 
pills are not contraindicated in diabetes. They should be 
examined in accordance with standard contraindications 
for hormonal contraceptives. Furthermore, patients sho-
uld be able to make informed decisions about preferred 
contraceptive method — following education in regards 
to the risk of unplanned pregnancy [1]. The recommended 
method of contraception for patients with diabetes lasting 
longer than 20 years, or with vascular complications (neph-
ropathy/retinopathy/neuropathy) is an intrauterine device 
(IUD) or progestin-only pills [2].
Target glycemic levels
It is recommended that a patient uses contraceptives 
until achieving optimal metabolic balance in the course 
of diabetes. It is essential that throughout pregnancy, and 
during the pregnancy planning period, patients achieve 
fasting and preprandial glucose levels of 70–90 mg/dl 
(3.9–5.0 mmol/L); maximum glucose levels 1 hour after 
meal: < 140 mg/dL (< 7.8 mmol/L); nighttime glucose be-
tween 2 and 4 a.m. > 70–90 mg/dL (> 3.9–5.0 mmol/L).
To evaluate the retrograde effectiveness of therapy 
occurring in the last 3 months, glycosylated hemoglobin 
(HbA1c) test is used. The recommended HbA1c level dur-
ing the period of planning pregnancy and during the first 
trimester is < 6.5%. It should be < 6% for 2nd and 3rd trimester.
Maintaining HbA1c < 6.5% (48 mmol/mol) during 
pre-conception period is linked to the lowest risk of fetal 
birth defects [3, 4]. 
The presented therapeutic goals provide optimal meta-
bolic balance. In circumstances were such goals cannot be 
safely reached (risk of hypoglycemia), it is recommended 
that the goals be set at a less restraining level based on 
clinical experience and personalized care.
During the pregnancy planning period, type 2 diabetes 
patients should be switched from oral therapy to insulin 
therapy. Metformin is acceptable only during the pre-con-
ceptual period provided that therapeutic doses ensure op-
timal metabolic control.
The use of metformin in women with diabetes type 
2 is also allowed during the preconception period only if 
it provides the optimal control of the metabolic balance.
It is recommended that doctors providing care to wom-
en with diabetes type 2 of childbearing age discuss patients’ 
plans for procreation on a regular basis — informing about 
the importance of planning pregnancy for reasons of risk 
of adverse obstetric outcomes in their population: coexist-
ing obesity, dyslipidemia, hypertension treated with drugs 
that are contraindicated in pregnancy, advanced age at 
conception, lack of habitual intensive glycemic self-control.
Ocular examination
Patients with diabetes who are planning pregnancy 
should be informed about recommendations towards 
having undergone a fundoscopic examination in the past 
6 months and then annually if no retinopathy is detected 
during first examination. 
Patients should also be informed that an abrupt correc-
tion of metabolic balance in diabetes might lead to worsen-
ing of retinal changes [5, 6].
Evaluation of kidney function
During the process of planning pregnancy and prior 
to cessation of contraception, patients with diabetes are 
recommended to perform kidney function tests in effort 
to evaluate presence of albuminuria. Patients presenting 
Table 1. Classification of pregestational diabetes (modified P. White classification)
Class A* Sufficient glycemic control with diet alone; any duration of diabetes*
Class B** (B1 and B2) Onset after 20 years of age or duration less than 10 years**
Class C Onset between 10 and 19 years of age or duration of 10–19 years
Class D Onset before 10 years of age or duration more than 20 years or retinopathy or hypertension
Class R Proliferative retinopathy or hemorrhage to the vitreous 
Class F Nephropathy; Proteinuria before pregnancy > 0.5 g/24 h
Class RF Both criteria of class R and F
Class H Coronary artery disease, cardiomyopathy 
Class T Post kidney transplant
* patients with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) 
** diabetes type 2 before pregnancy
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with abnormal results of kidney function tests (blood cre-
atinine ≥ 120 μmol/L and/or urine albumin: creatinine ra-
tio > 30 mg/mmol and/or estimated glomerular filtration 
rate eGFR < 45 mL/min/1.73 m2), should be consulted by 
a nephrologist.
Patients should be advised that advanced kidney dis-
ease significantly increases the risk of complications during 
pregnancy, including preeclampsia and premature birth. 
Moreover, the risk correlates with the stage of kidney dis-
ease; there are also studies describing the progression of 
kidney disease during pregnancy [7–9]. 
Evaluation of cardiovascular system
Patients with following risk factors should be consulted 
by a cardiologist during the pregnancy planning period 
[10, 11]:
1. Presence of symptoms suggestive of coronary artery 
disease, limited exercise tolerance and/or congestive 
heart failure
2. Abnormal ECG results mentioned in patient history
3. Atherosclerotic changes in the carotid or peripheral 
arteries evidenced in patient history
4. Diabetes lasting longer than 15 years
5. In addition to diabetes presence of two or more ischemic 
heart disease (IHD) risk factors:
a) Age above 35
b) Abnormal lipid profile
c) Hypertension
d) Smoking
e) Family history of early onset atherosclerosis
f ) Albuminuria (microangiopathy)
g) Autonomic neuropathy (macroangiopathy)
Successfully treated coronary artery disease (phar-
macologically, PCI, and/or surgically) is not a contrain-
dication for pregnancy [12].
Evaluation of thyroid function
Evaluation as per recommendations of the Polish En-
docrinology Society and the Polish Diabetology Society 
[13, 14].
Folic acid supplementation
Patients planning pregnancy should begin folic acid sup-
plementation at least 12 months prior to becoming pregnant, 
with continued supplementation throughout the entire preg-
nancy, and during the postpartum and lactation periods.
The recommended supplementation for high-risk 
groups (pregestational diabetes type 1 and 2) is a folic acid 
dose of 0.4 mg/24 h, increased by another 0.4 mg dose, 
preferably in the form of activated folic acid. It is recom-
mended that the supplemented formulations be enriched 
with vitamin B12 [15].
Vitamin D supplementation
The recommended dosage of vitamin D supplements 
for a pregnant patient is 1500–2000 IU per day, while the 
recommended dose for patients with BMI > 30 kg/m2 may 
reach 4000 IU/24 h [16].
Selected medications and their safety in early 
pregnancy
Angiotensin-converting enzyme inhibitors (ACEI), angio-
tensin II receptor blockers (ARB), and statins should be ceased 
prior to conception, or as soon pregnancy is confirmed [17–19].
Safety of human insulin in pregnancy is well established; 
the most commonly used being short acting recombined 
human insulin (short acting analogs like Lispro and Aspart), 
intermediate acting recombined human insulin (NPH insu-
lin) and long acting insulin analog Detemir (all mentioned 
types of insulin are classified into class B by FDA). Short act-
ing insulin analog Glulisine and long acting insulin analog 
Glargine are categorized as class C according to the FDA. 
Long acting insulin analog Degludec has not yet been clas-
sified by the FDA.
Remaining diabetes medication has been classified by 
FDA as class B (metformin) or class C (sulfonylureas, pi-
oglitazone, dapagliflozine, GLP-1 analogs). In regards to 
DPP4 antagonists, there is not yet enough research in the 
international journals about their safety in pregnancy.
It is contraindicated for a diabetic patient to get 
pregnant, when following clinical situations apply: 
1. Nephropathy with creatinine clearance below 40 mL/min
2. Proliferative retinopathy resistant to treatment.
3. Cardiac complications:
a) Advanced ischemic heart disease not viable for 
treatment, hypertrophic cardiomyopathy or severe 
ventricular dysfunction (LVEF < 30%, NYHA III/IV). 
b) Previous perinatal cardiomyopathy, with any sort of 
residual dysfunction of left ventricle.
4. Autonomic neuropathy of the heart or gastrointestinal 
tract.
It is important to emphasize that any decision deal-
ing with pregnancy belongs to the patient. Nevertheless, 
such individuals need to be informed by specialists about 
the risks associated with pregnancy in regards to patient 
health and life.
1.1.2. Medical care of a patient  
with pregestational diabetes mellitus during  
her pregnancy
In situations where pregnancy is unplanned and not 
managed by any specialized medical centre, it is strongly 
recommended to refer such patients as soon as possible. 
Treatment involves reaching therapeutic goals in gly-
cemia levels. Depending on the progression of pregnancy, 
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hyperglycemia has different effects on the fetus. In the first 
trimester it significantly increases the rate of birth defects 
and miscarriage [20, 21].
The negative effect of hyperglycemia is a sort of con-
tinuum, where an increasing degree of glycemia increases 
proportionally the risk of adverse outcomes. The best results 
are achieved when glucose levels are close to levels set as 
goals [22, 23].
However, the patient should avoid excessively low glu-
cose levels for reasons such as maternal hypoglycemia, or 
small for gestational age fetus. 
Patients should be informed that pregnancy can af-
fect glycemia control; in particular, pose an increased risk 
of severe hypoglycemia and increases demand for insulin 
during second half of pregnancy [11, 24].
Medical care of patients with PGDM should always be 
individualized.
Given the risks associated with pregnancy complicated 
with diabetes, it is recommended that routine visits in a spe-
cialized medical facility be scheduled at least every 2 weeks. 
Insulin therapy
Insulin therapy is the recommended pharmacotherapy 
for pregnant women, regardless of diabetes type. Studies 
have shown that short acting insulin analogs (Aspart and 
Lispro) are more effective than human insulin in controlling 
postprandial glucose levels. There was no significant differ-
ence in obstetric outcomes [25].
Patients on insulin should be informed about the neces-
sity of carrying fast-acting glucose (dextrose capsules, drinks 
rich in glucose) in the event of hypoglycemia. 
In case of severe hypoglycemia, it is recommended 
to administer glucagon, which every patient with type 
1 diabetes should be equipped with. Training on the use 
of glucagon should be offered to both the patient and 
her family.
Randomized studies concerning obstetric outcomes 
in patients with diabetes type 1 indicated no difference 
between patients using multiple daily injections (MDI) and 
patients using continuous subcutaneous insulin infusion 
(CSII) [26]. The decision about starting insulin pump therapy 
in a patient using MDI should be analyzed on an individual 
level. In particular, insulin pump therapy might be recom-
mended for patients with recurrent episodes of hypoglyce-
mia, especially occurring during the night [27]. Such groups 
of patients can benefit from a continuous glucose monitor-
ing system (CGMS) [28, 29].
Diabetic diet
A diabetic diet is the basis of treatment for diabetes.
Patient with pregestational diabetes should receive 
a personalized dietary consultation that takes into account: 
pre-pregnancy BMI, physical activity level, dynamics of fetal 
growth and the recommended increase of maternal weight 
during pregnancy. An excessive increase of maternal weight 
can increase the risk of fetal macrosomia, which increases 
the risk of fetal injury during labor, the risk of caesarian sec-
tion and obesity in the future [11].
An optimal range of body weight increase should be 
defined from pre-pregnancy BMI during first pregnancy 
checkup visit (Tab. 2).
A meal plan should be established together with the 
patient. Food intake should occur regularly and consist-
ently throughout the day, with main meals and snacks that 
contain a proper amount of calories, including proteins 
(1.1 g/kg/24 h), fats (with < 10% of saturated fats) and 175 g 
of ingestible carbohydrates per 24 h.
A diabetic diet assumes a balanced composition (40– 
–50% carbohydrates, primarily with low glycemic index, rich 
in starch and with limited amounts composed of processed 
flour; 20–30% of proteins of animal and plant origin (equal 
proportions); 20–30% of fats with the dominance of unsatu-
rated fats of plant origin rich in omega-3, with a daily caloric 
intake adjusted to pre-gestational BMI, physical activity and 
age. A pregnant patient with normal BMI should consume 
30 kcal per kg of body weigh/24 h; the daily caloric intake 
for a pregnant woman should range from 1800 to 2500 kcal.
The daily meal plan should consist of 3 main meals 
and 3 snacks (first and second breakfast, lunch, afternoon 
snack, dinner, snack before bed). Fruits and simple car-
bohydrates should be integrated with main meals. Such 
division and meal composition guarantees a stable transfer 
Table 2. Gestational weight gain recommendations (by Institute of Medicine, USA) in regards to pre-pregnancy BMI and daily caloric intake [30] 
Pre-gestational BMI or BMI during first 
obstetric evaluation [kg/m2]
Recommended gestational weight gain  
(in [kg])
Recommended caloric intake  
per kg of body weight
< 19.8 12.5–18.0 35–40
19.8–26.0 11.5–15.9 30–32
26.1–29.0 7.0–11.4 25–30
29.1–34.9 below 7.0 24–25
> 35.0 below 7.0 15–17
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of nutrition to the fetus and allows for a better metabolic 
control of diabetes. The meal before bed is especially im-
portant; it prevents nighttime hypoglycemia and fasting 
ketogenesis. The bedtime meal should contain approxi-
mately 25 g of carbohydrates with a low glycemic index or 
products containing resistant starch. Morning ketonemia in 
a metabolically unbalanced patient can lead to intellectual 
disability and psychomotor retardation in her offspring [31].
Monitoring glycemia
Daily glycemic control is recommended for every 
pregestational diabetes patient on intensive insulin therapy. 
The control relates to fasting glucose levels in the morning, 
glucose levels before and 1h following meals, and levels 
before sleep. Periodically, it is also recommended to control 
nighttime glucose levels between 2 and 4 AM. Patients with 
type 2 diabetes, who are treated with diet alone or with one 
dose of intermediate or long acting insulin, should control 
their fasting glycaemia and 1h after meals (Tab. 3).
Evaluation of ketoacidosis 
Patients with type 1 diabetes should carry strips that 
can detect ketone bodies in the urine. Urine ketone bodies’ 
measurement should be performed when glycemic levels 
are above 200 mg/dL. If ketones are detected patient should 
seek doctor [11].
In case ketoacidosis is suspected, patient should be 
referred to a facility with both obstetric ward and intensive 
care unit.
Ocular evaluation
Patients with pregestational diabetes, who have not 
undergone a fundoscopic examination in the past 3 months, 
should be examined as soon as possible and subsequently in 
the 28th week of pregnancy. Patients diagnosed with retin-
opathy during their first visit should undergo an additional 
retinal exam between the 16th and 20th week of pregnancy.
Patients with a diagnosed retinopathy should undergo 
an ophthalmologic control 6 months after labor.
In cases of progressive retinopathy during pregnancy i.e. 
neovascularization or a clinically significant macular edema, 
laser therapy should be considered.
The presence of retinopathy alone is not an indication 
to terminate pregnancy via C-section. An ophthalmologist 
experienced in managing patients with diabetic retinopathy 
should advise recommended method of birth based on ocu-
lar indications. Nevertheless, in cases of neovascularization 
with the consequent risk of retinal hemorrhage, patients 
should avoid strong pushes during the second stage of 
labor or preferably be offered a C-section [11].
Assessing kidney function
If kidney function has not been assessed in the past 
3 months, it should be assessed during the initial visit at 
a reference center. If plasma creatinine concentration is 
elevated (plasma creatinine ≥ 120 µmol/L and/or urine 
albumin:creatinine ratio > 30 mg/mmol or 24h urine pro-
tein > 0.5 g) the patient should be consulted by a nephrologist.
Estimated glomerular filtration rate (eGFR) should not 
be used to assess kidney function during pregnancy.
Arterial hypertension, including pregnancy-induced 
hypertension, should be closely monitored and treated. 
Based on observational studies, gestational diabetes mel-
litus (GDM) blood pressure targets of 110–129/65–79 mmHg 
may halt the progression of nephrological changes and 
prevent the development of preeclampsia [32, 33].
The recommended pharmacotherapeutic agents for 
treating hypertension during pregnancy complicated with 
diabetes are methyldopa, long-acting calcium channel 
blockers, and selective beta-blockers. Patients should also 
be advised to monitor their salt intake and body mass [34].
Preeclampsia prophylaxis
Patients with pregestational diabetes (type 1 and type 2) 
should take acetylsalicylic acid in the dose of 1 mg/kg of 
body weight (75–150 mg/day) from 12th to 34th week of 
pregnancy [35–39]. In our opinion, such prophylaxis should 
be indicated particularly in patients with a long history of 
diabetes with vascular complications, as well as, in patients 
with preeclampsia in previous pregnancies.
2. HYPERGLYCEMIA FIRST DETECTED  
DURING PREGNANCY
2.1. Hyperglycemia first detected during 
pregnancy — definition, classification  
and diagnostic criteria.
Hyperglycemia first detected during pregnancy is de-
fined as a various degree of glucose intolerance with onset 
or first recognition during pregnancy. Women whose hyper-
glycemia developed as a result of insufficient compensa-
Table 3. Glycemic goals in pregnant patients — self-control with 
a glucometer
Glucose measurement
Glucose level
[mg/dL] [mmol/L]
Fasting 70–90 3.9–5.0
1h after meal < 140 < 7.8
Between 2 and 4 am > 70–90 > 3.9–5.0
Average 24 h glycemia < 110* 6.1
*Kitzmiller 2008 [11]
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tion of natural processes during pregnancy constitute the 
majority of this group.
A certain percentage of these women may have suf-
fered from diabetes (mainly type 2) before their pregnancy 
without being diagnosed. This distinction has an important 
prognostic value to both pregnant women and their fe-
tuses. For this reason, we propose the following classification 
and diagnostic scheme [10, 40, 41]:
2.1.1. Diabetes in pregnancy (DIP)  
— when blood glucose values in a pregnant woman 
exceed the levels necessary  
for the diagnosis of clinically overt diabetes, i.e.:
1. fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) OR
2. plasma glucose 2 hours after a 75 g oral glucose toler-
ance test (OGTT) ≥ 200 mg/dL (11.1 mmol/l) OR
3. random plasma glucose ≥ 200 mg/dl (11.1 mmol/L) with 
clinical symptoms of hyperglycemia
2.1.2. Gestational diabetes mellitus (GDM)  
— when blood glucose values in a pregnant woman 
meet at least one of the diagnostic criteria (Tab. 4)
2.2. The effect of gestational hyperglycemia  
on fetal development, newborn health  
and beyond
In a pregnancy complicated by hyperglycemia first de-
tected in pregnancy, carbohydrate metabolism disturbances 
and accompanying disorders of lipid metabolism occur usu-
ally in the second half of pregnancy; therefore, the main disor-
der accompanying this complication is excessive fetal weight 
(LGA, or large for gestational age, is a fetus above the 90th 
percentile of weight for its gestational age), or macrosomia 
defined as a fetus with a mass above 4200 g. These disorders 
may lead to shoulder dystocia, perinatal trauma and may be 
associated with a growing percentage of assisted deliveries.
Newborns with excessive birth weight often suffer from 
metabolic disturbances. Most typically, they suffer from hy-
poglycemia in the early perinatal period and have a higher 
risk of developing a cardiovascular disease — as well as 
obesity or type 2 diabetes. Randomized studies performed 
in recent years have shown that, when left untreated, even 
moderate carbohydrate tolerance disorders are associated 
with significantly increased risk of neonatal complications, 
while the implementation of therapy limits the incidence.
2.3. Diagnosis of diabetes during pregnancy  
— management
2.3.1. Diagnostic algorithm for hyperglycemia 
during pregnancy
Fasting blood glucose (FBG) should be ordered by a gy-
necologist as a routine laboratory test for all women in early 
pregnancy upon initial contact. Due to the differences in car-
bohydrate metabolism that occur during pregnancy, it is advis-
able to instruct the pregnant women before conducting the 
test that the break between her last meal and the test should 
last 8–10 hours. The break should not exceed that period since 
prolonged fasting may elevate fasting blood glucose.
a) FBG below 92 mg/dL and no GDM risk factors — the 
patient should be qualified for GDM testing between 
the 24th and 28th week of pregnancy.
b) FBG below 92 mg/dL and at least ≥ 1 GDM risk factor:
•	 BMI before pregnancy ≥ 30 kg/m^2
•	 GDM present in previous pregnancy 
•	 family history (in first degree blood relatives) of 
type 2 diabetes
•	 giving birth to a child with a birth weight equal 
to, or over, 4.5 kg 
a 75 g OGTT should be ordered right away and if the 
results are within the normal range a repeated 75 g OGTT 
should be ordered between the 24th and 28th week of preg-
nancy.
c) FBG 93–125 mg/dL — immediately perform a 75 g 
OGTT
d) FBG 126 mg/dl or above — repeat the test and if 
the result is still ≥ 126 mg/dL a diagnosis “diabetes 
detected in pregnancy” should be made and the 
patient should be directed to a reference centre 
specialized in treating pregnant diabetics, without 
the need to perform OGTT. However, if the result of 
the repeated FBG is equal to 125 mg/dL or less, a 75 g 
OGTT should be ordered immediately.
e) 120 minute glucose plasma concentra-
tion ≥ 200 mg/dL — a diagnosis “diabetes detected 
in pregnancy” should be made and patient should 
be referred immediately to a reference centre spe-
cialized in treating pregnant diabetics.
f ) random plasma glucose ≥ 200 mg/dL — a diag-
nosis “diabetes detected in pregnancy” should be 
made and patient should be referred immediately 
to a reference centre specialized in treating pregnant 
diabetics, without the need to perform an OGTT.
Table 4. Diagnostic criteria of GDM [WHO 2013, IADPSG]
Glucose measurement  Plasma glucose concentration
[mg/dL] [mmol/L]
Fasting 92–125 5.1–6.9
60 minutes ≥ 180 ≥ 10
120 minutes 153–199 8.5–11.0
Because of differences in treatment, GDM is divided into two types: 
G1DM — normoglycemia is attained by diet 
G2DM — normoglycemia is attained by pharmacotherapy
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g) in patients managed with diet and diagnosed with 
impaired glucose tolerance (IGT), or impaired fasting 
glucose (IFG) before pregnancy, a diagnosis of class 
A pregestational diabetes mellitus (PGDM) should 
be made upon confirmation of pregnancy and the 
patient should be directed to a reference centre 
specialized in treating pregnant diabetics, without 
the need to perform an OGTT.
h) if patient is treated with metformin prior to pregnancy 
due to insulin resistance, it is recommended to con-
tinue therapy and begin glucose monitoring (fasting 
and one hour following main meals) until the end of 
the first trimester. A 75 g OGTT should be performed 
seven days after discontinuing metformin.
2.3.2. Conditions of performing a 75 g oral glucose 
tolerance test
For the diagnosis of hyperglycemia during pregnancy, 
a single stage procedure is recommended in the form of a 75 g 
oral glucose tolerance test, performed on an empty stomach. 
Testing venous plasma is the recommended method.
a) the test should be performed 8–10 hours after the 
last meal;
b) for at least 3 days prior to the test, the pregnant 
woman should consume a diet with standard 
amounts of carbohydrates (not less than 150 g of 
carbohydrates provided normal activity level);
c) the solution consisting of 75 g of glucose dissolved 
in 250–300 mL of water must be consumed within 
5 minutes;
d) during the duration of the test, the patient must sit 
and cannot eat or smoke cigarettes;
e) blood is drawn during the fasting state, at one hour 
and two hours after drinking the glucose solution;
f ) if glucocorticosteroids have been given to the pa-
tient in order to stimulate fetal lung development, 
the test must be delayed until at least 72 hours after 
the glucocorticosteroid cycle is complete; likewise, 
the test should not be performed when the patient 
is on intravenous beta-adrenergic agonist therapy.
2.3.3. Other laboratory tests
a) it is advisable to measure HbA1c at the time of di-
agnosis of GDM, especially in patients diagnosed 
during the first trimester, since the test may confirm 
or rule out the existence of undiagnosed type 2 DM 
[42]. In the event of detecting HbA1c ≥ 6.5%, at the 
moment of diagnosing GDM, the patient should be 
directed to a reference centre specialized in treating 
pregnant diabetics.
b) it is not recommended to periodically monitor 
HbA1c values in pregnant women with hypergly-
cemia. However, it is advisable to monitor this pa-
rameter in clinically doubtful situations as a support 
for the decision to begin insulin therapy.
c) it is advisable to consider measuring triglycerides 
concentration as an independent risk factor for 
fetal macrosomia and preeclampsia, especially in 
pregnant women in whom hyperglycemia coexists 
with obesity.
2.4. Treatment of hyperglycemia during 
pregnancy
2.4.1. Diet and physical activity
A diabetic diet, combined with appropriately selected and 
structured physical activity, and an optimization of weight 
gain in pregnancy, is the basis of hyperglycemia therapy dur-
ing pregnancy [40]. It is advisable that a pregnant woman di-
agnosed with diabetes in pregnancy/gestational diabetes 
mellitus be under the care of a nutritionist, trained in control-
ling glycemia and aided in modifying her lifestyle [42].
The caloric content of the diet should reflect the recom-
mended gestational weight gain appropriate to her preges-
tational BMI (refer to Table: Recommended daily calories, 
as in PGDM).
Patients should be encouraged to self-monitor glucose 
levels while fasting and an hour after main meals. In unusual 
cases (e.g. if during a 75 g oral glucose tolerance test the 
glucose measured at two hours is higher than one hour after 
loading; or after a high fat meal) patients may be advised to 
measure blood glucose two hours after the start of the meal. 
The main goal of glucose self-monitoring is to capture the 
highest levels of postprandial glycemia. Randomized trials 
conducted on small groups of pregnant women with GDM 
have shown that properly selected physical exercises have 
a beneficial effect on blood glucose levels. Physical activ-
ity of light to moderate intensity, such that engages large 
muscle groups, is particularly recommended for pregnant 
women (walking, Nordic walking, swimming, aqua-aerobics, 
aerobic exercises, cycling, yoga). The exercise session should 
begin and end with a few minutes of warm-up and stretch-
ing. The optimal duration of the actual practice session is 
30 minutes for most days of the week (minimum 150 min-
utes per week). Women who did not regularly exercise be-
fore their pregnancy should start with 10-minute sessions 
and gradually increase their duration [11].
2.4.2. Pharmacotherapy
Immediate implementation of therapy with long-acting 
insulin is advisable if FBG ≥ 126 mg/dL.
In 10–40% of pregnant women with hyperglycemia 
diagnosed during pregnancy, diet modification and physi-
cal activity alone is insufficient to achieve therapeutic goals 
(see Table: Target values  for blood glucose during pregnancy 
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— self-monitoring with a glucometer). In cases of persistent 
hyperglycemia, following a few days of properly imple-
mented diet and lifestyle modifications, insulin therapy is 
the treatment of choice.
Oral anti-diabetic drugs are not currently considered 
standard therapy for hyperglycemia during pregnancy.
It is also advisable to intensify glycemic control and 
to consider a modification of therapy (addition of insulin 
therapy) in cases of ultrasonographic evidence of maternal 
hyperglycemia in the fetus (polyhydramnion, accelerated 
intrauterine growth, the significant disproportion of fetal 
head to stomach circumference) despite normal glycemic 
values reported by patient.
The goal of therapy is to achieve stable normoglyce-
mia and to avoid violent fluctuations in blood glucose 
levels — hypoglycemia in particular. Due to the observed 
phenomenon of accelerated starvation during pregnancy, 
an excessive reduction of carbohydrate intake may lead 
to ketonuria. Therefore, it is recommended to periodically 
check this parameter. If acetone levels (in urine) persist 
despite administering additional insulin dose in cases of 
hyperglycemia or consuming carbohydrates in hypoglyce-
mia, it is necessary to continue therapy in a hospital setting.
3. FETAL MONITORING IN PREGNANCY 
COMPLICATED WITH DIABETES
3.1. Ultrasonographic examination  
and monitoring of fetal well-being
Since a high percentage (over 70%) of women with 
type 1 diabetes suffer from menstrual cycle disorders, hy-
perandrogenism and polycystic ovary syndrome (PCOS), it 
is recommended to carefully assess and possibly correct 
gestational age with the use of ultrasound examination 
during the first trimester and to compare the result with 
the date of last menstrual period [43].
The indications for conducting a first trimester com-
bined test in the 11th–14th weeks of pregnancy, as part of 
government-guaranteed healthcare services (ultrasound 
evaluation of chromosomal aberration markers + assess-
ment of serum biochemical markers), are determined on 
the basis of typical risk factors (age above 35, family history 
of chromosome aberrations and/or suspected abnormali-
ties during routine first trimester ultrasound examination).
Due to increased risk of structural defects of the fetus, 
a PGDM patient should be provided with fetal anatomy as-
sessment, including fetal heart evaluation at 18–22 weeks in 
accordance with the guidelines of the Polish Gynecological 
Society [44].
Due to increased risk of fetal growth disorders, a PGDM 
patient should be provided an ultrasound examination of 
fetal growth and amniotic fluid levels regularly, at least every 
4 weeks starting from the 28th week of pregnancy.
Routine assessment of fetal well-being, including Dop-
pler is not recommended in patients with PGDM. It should 
rather be considered for patients at high risk of intrauterine 
growth restriction: hypertensive patients and patients with 
vascular complications of diabetes — diabetic nephropathy 
in particular [45].
In cases of hyperglycemia during pregnancy initially de-
tected during the first trimester, undiagnosed PGDM should 
be suspected. For this reason, ultrasonographic monitoring 
should be conducted in reference centers specialized in the 
treatment of pregnant patients with diabetes.
It is recommended that daily fetal movement recording 
(DFMR) be conducted after the 28th week of pregnancy. 
After the 36th week of pregnancy, cardiotocography with 
non-stress test (NST) is recommended during each clinical 
visit and/or daily in hospitalized patients.
Ultrasonographic fetal monitoring should be conducted 
according to the standards for normal pregnancy and supple-
mented with additional ultrasound screenings between the 
28th and 36th weeks of pregnancy — to assess fetal growth, 
amniotic fluid levels and macrosomia risk factors [42].
A biophysical profile (BPP) and Doppler sonography flow 
tests can be considered in cases of improper fetal growth 
(both SGA and LGA), and in other conditions such as preec-
lampsia.
Women with GDM should be advised to monitor fetal 
movements with the “count-to-ten” method if any irregulari-
ties are noticed immediately report them to the doctor. The 
patient should also be advised to report to the physician any 
observations of reduced or unusual fetal movements after 
the 28th week of pregnancy.
 
No specific fetal surveillance protocol has been 
shown to reduce perinatal mortality in pregnancies com-
plicated with diabetes. If monitoring of fetal well-being 
is recommended, the frequency of such tests should 
take into account fetal growth dynamics, a volume of 
amniotic fluid and co-existence of additional obstetric 
complications.
4. CHILDBIRTH
Childbirth in a patient with PGDM or hyperglycemia 
diagnosed during pregnancy should take place in a center 
that is experienced in managing pregnancies complicated 
with diabetes and possesses an intensive neonatal care unit.
Neither PGDM nor GDM is a contraindication for a natu-
ral delivery.
Induction of labour after the 38th week of pregnancy 
should be considered in PGDM patients due to an increased 
risk of complications.
According to recommendations of Polish Society of Gy-
necologists and Obstetricians, in the event of an estimated 
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fetus weight exceeding 4000 g, and the difference between 
AD and BPD exceeding 2.6 cm, induction of labor is contrain-
dicated due to increased risk of shoulder dystocia [46]. The 
risk of shoulder dystocia can also be assessed by measur-
ing AC and head circumference (HC). Clinical observations 
show that when this difference (AC-HC) exceeds 4 cm, the 
risk increases significantly.
Cardiotocographic supervision of pregnant 
woman should be implemented beginning from the 38th 
week of pregnancy.
During labour, it is recommended to monitor capillary 
blood glucose every hour (glucose concentration should 
be in the range of 70–120 mg/dL).
Depending on blood glucose levels, intravenous infu-
sion of either glucose or insulin in a NaCl solution (infusion 
pump, 1 IU/mL, with a blood glucose-dependent infusion 
rate) may be considered.
A patient with GDM may continue pregnancy until spon-
taneous delivery during the 39th–40th week of pregnancy 
provided that: the disease is well managed, patient adheres 
to the principles of treatment, no other maternal or fetal 
complications coexist and the estimated fetal weight is be-
tween the 10th and 90th percentile, or does not exceed 4000 g. 
Individuals with poorly managed GDM, or other maternal 
and/or fetal pathologies, should be individually assessed (at-
tention should be paid to hypertension, preeclampsia, LGA 
and mother’s age > 40 years). When planning how to resolve 
pregnancy, the risk of shoulder dystocia should be taken into 
account for patients with gestational diabetes.
5. POSTPARTUM CARE
PGDM patients on insulin therapy require a reduction 
of insulin dose immediately after delivery (approximately 
50% reduction).
Breastfeeding is not contraindicated in patients with 
PGDM.
The patient should be informed that breastfeeding may 
promote hypoglycemia.
Patients with type 2 DM who have used metformin prior 
to pregnancy may resume therapy with this agent during 
breastfeeding [47].
PGDM patients in postpartum period should be in-
formed about the importance of using adequate contra-
ception to prevent unplanned pregnancies.
Patients with GDM should be encouraged and moti-
vated to breastfeed for a minimum of 6 months.
In cases of GDM treated with diet alone, the patient 
should be encouraged to self-monitor her glucose levels 
while fasting, and two hours after main meals, for a few days 
after childbirth. If blood glucose levels are within normal 
range, glycemic control can be discontinued.
In cases of GDM treated with insulin, therapy should be 
discontinued right after delivery while glucose monitoring 
should be performed when fasting and two hours after main 
meals. It is recommended to consider additional glycemic 
controls between 11:00 PM and 3:00 AM.
It is recommended to perform a 75 g oral glucose toler-
ance test six weeks after delivery with the results interpreted 
according to WHO guidelines for the general population). In 
case of negative OGTT results, the test should be repeated 
every year [10].
According to international recommendations, HbA1c 
measurements should be performed 6–13 weeks after de-
livery. Patients with HbA1c ≥ 6.5% should be diagnosed 
with diabetes mellitus and referred to specialist care [40].
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